Multiple sclerosis relapses/exacerbations

Relapsing-remitting multiple sclerosis Exacerbation of multiple sclerosis... 

Multiple sclerosis (MS) - For the treatment of relapsing forms of MS to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations. 

Indications Treatment of ambulatory patients with relapsing-remitting multiple sclerosis to reduce the frequency of clinical exacerbations... 

B. Indications and nse Betaseron is indicated for use in ambulatory patients with relapsing-remitting multiple sclerosis to reduce the frequency of chnical exacerbations. The safety and efficacy of Betaseron in chronic-progressive MS has not been fully evaluated. 

Recommended dosage and monitoring requirements For prevention of exacerbations in patients with relapsing-remitting multiple sclerosis, the recommended dose of Betaseron is 0.25 mg injected subcutaneously every other day. 

E Role in therapy Betaseron is useful for reducing symptomatic exacerbation in multiple sclerosis (MS) patients with relapsing-remitting disease. The drug should be considered in patients with ch-nically deflnite or laboratory-supported definite disease. It is not indicated in those patients with primary progressive MS. Interferon beta-la (Avonex) has also demonstrated activity in MS patients. 

B. Indications and nse Rebif is indicated for the treatment of patients with relapsing forms of multiple sclerosis to decrease the frequency of clinical exacerbations and delay the accumulation of physical disability. 

E. Therapeutic response Two studies evaluated the safety and efficacy of Rebif in patients with relapsing-remitting multiple sclerosis. Study 1 was a placebo-controlled, 2-year trial in 560 patients with multiple sclerosis for at least 1 year. The primary efficacy end point was the number of clinical exacerbations. The mean numbers of exacerbations per patient over 2 years was 1.82 and 1.73 in those who received either 22 pg or 44 pg three times per week compared with a mean number of 2.56 in those who received placebo. The decrease in the number of exacerbations in the Rebif groups compared with the placebo group was statistical significant, but the difference between... 

Finally, certain interferons may decrease exacerbations of multiple sclerosis (MS).36 88 Specifically, interferon beta-la (Avonex) and interferon beta-lb (Betaseron) may help reduce the incidence and severity of relapses in exacerbating-remitting MS.36 64 This... 

Interferon beta-lb is admini.stered SC to decrease the frequency of clinical exacerbation in ambulatory patients with relapsing-remitting multiple sclerosis (RRMS). RRMS is characterized by unpredictable attacks resulting in neurological deficits, separated by variable periods of remission. 

Interferon beta-la (Avonex, Rebif), a 166-amino acid recombinant glycoprotein, and interferon beta-lb (Beta-seron), a 165-amino acid recombinant protein, have antiviral and immunomodnlatory properties. They are PDA approved for the treatment of relapsing and relapsing-remitting multiple sclerosis to reduce the frequency of clinical exacerbations. The mechanism of their action in mnltiple sclerosis is unclear. 

Interferon beta-la is an interferon beta, which has antiviral, antiproliferative, and immunoregulatory activities. It binds to specific cell membrane receptors that induce the expression of a number of gene products that mediate the biological actions of interferon beta-la. It is indicated for the treatment of relapsing forms of multiple sclerosis to slow accumulation of physical disability and decrease the frequency of clinical exacerbations. 

---